Entremed News (NASDAQ:ENMD)
| Latest Entremed News Headlines | | Date | Time | Source | | | 06/13/2008 | 7:00AM | PRNUS | EntreMed to Present at the BIO 2008 Annual International Convention
ROCKVILLE, Md., June 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview during the... More...>> |
| 06/11/2008 | 7:00AM | PRNUS | EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
Patent Covers Compositions and Methods
ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the issuance of U.S. Patent No. 7,371,741 covering analogs of 2... More...>> |
| 06/02/2008 | 7:00AM | PRNUS | EntreMed's ENMD-2076 Demonstrates Antitumor Activity in Multiple Myeloma Model
Preclinical Data Support Rationale for Clinical Study
ROCKVILLE, Md., June 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical data for its Aurora... More...>> |
| 05/13/2008 | 7:00AM | PRNUS | EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Rodman... More...>> |
| 05/08/2008 | 7:00AM | PRNUS | Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Dana-Farber and Colorado Treating Patients with ENMD-2076
ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that Dana-Farber Cancer Institute has joined the... More...>> |
| 05/02/2008 | 7:00AM | PRNUS | EntreMed Reports First Quarter 2008 Financial Results
ROCKVILLE, Md., May 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial results for the three months ended March 31, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO... More...>> |
| 04/22/2008 | 4:08PM | PRNUS | EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that the Company's Board of Directors has decided against seeking stockholder approval for a reverse... More...>> |
| 04/16/2008 | 7:00AM | PRNUS | EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Compounds Demonstrate Potent Antitumor Activity in a Variety of Tumor Types
ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical... More...>> |
| 04/14/2008 | 7:00AM | PRNUS | EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
New Drugs on the Horizon Session Highlights New Small Molecule Drug Candidates
ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical... More...>> |
| 04/09/2008 | 7:00AM | PRNUS | EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
Selective Kinase Inhibitor Phase 1 Trial in Advanced Cancer Patients
ROCKVILLE, Md., April 9, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a Phase... More...>> |
| 04/07/2008 | 3:00PM | PRNUS | Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
ROCKVILLE, Md., April 7, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the retirement of Ronald E. Cape, Ph.D. as Director, effective June 5, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO... More...>> |
| 04/04/2008 | 5:38PM | PRNUS | EntreMed Receives Nasdaq Deficiency Notice
ROCKVILLE, Md., April 4, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that on April 4, 2008, it received a Deficiency Notice from the Listing Qualifications Department... More...>> |
| 04/02/2008 | 7:00AM | PRNUS | EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
Phase 1 Study to be Conducted in Advanced Cancer Patients
ROCKVILLE, Md., April 2, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a Phase 1, open-label... More...>> |
| 03/25/2008 | 7:00AM | PRNUS | EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
ROCKVILLE, Md., March 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BioCentury... More...>> |
| 03/13/2008 | 11:00AM | PRNUS | EntreMed Announces 2008 Corporate and Clinical Program Priorities
ROCKVILLE, Md., March 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced its 2008 corporate and clinical program priorities. Formal remarks regarding corporate objectives, as... More...>> |
| 03/06/2008 | 7:00AM | PRNUS | EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
ROCKVILLE, Md., March 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three months and twelve months ended December 31, 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO... More...>> |
| 02/26/2008 | 7:00AM | PRNUS | EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
ROCKVILLE, Md., Feb. 26 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the Jesup... More...>> |
| 02/21/2008 | 7:00AM | PRNUS | EntreMed to Present at the 7th Annual North America Forum for Investing and Partnering in Biotech
ROCKVILLE, Md., Feb. 21 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the 7th... More...>> |
| 02/05/2008 | 7:00AM | PRNUS | EntreMed to Present at BIO CEO and Investor Conference
ROCKVILLE, Md., Feb. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BIO... More...>> |
| 01/28/2008 | 7:00AM | PRNUS | EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
Combination of Panzem(R) NCD and Avastin(R) May Slow Tumor Growth
ROCKVILLE, Md., Jan. 28 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ:ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results... More...>> |
|
|
|